The Outperform rating and price target of $120 by Credit Suisse analyst Tiago Fauth indicate a positive outlook for Biomarin Pharmaceutical. This news is likely to have a positive impact on the stock price in the short term as it suggests that the analyst believes the stock will outperform its peers.